Antitopoisomerase drug action and resistance

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 958-966

  Nitiss, J L ^a   Beck, W T ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACLARUBICIN; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); FOSTRIECIN; GLYCOPROTEIN P; GYRASE INHIBITOR; IRINOTECAN; MERBARONE; PROTEIN BCL 2; PROTEIN P53; RAZOXANE;

ACUTE LEUKEMIA; ANIMAL CELL; APOPTOSIS; CANCER CELL; CANCER RESISTANCE; DNA DAMAGE; DRUG ACCUMULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; YEAST CELL;

APOPTOSIS; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 0029944106     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00056-1     Document Type: Article

References (115)

1. Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv Clin Chem 1994, 31, 1-61.
2. Shustik C, Dalton W, Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 1995, 16, 1-78.
3. Grant CR, Validimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994, 54, 357-361.
4. Kruh GD, Chan A, Myers K, Gaughan K, Miki T, Aaronson SA. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res 1994, 54, 1649-1652.
5. Izquierdo MA, van der Zee AGJ, Vermorken JB, et al. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995, 87, 1230-1237.
6. Scheffer GL, Wijngaard PLJ, Flens MJ, et al. The drug resistance-related protein LRP is the human major vault protein. Nature Medicine 1995, 1, 578-582.
7. Beck WT, Danks MK, Wolverton JS, et al. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol 1994, 29B, 145-169.
8. Hochhauser D, Harris AL. The role of topoisomerase II alpha and beta in drug resistance. Cancer Treat Rev 1993, 19, 181-194.
9. L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Diff 1995, 6, 363-370.
10. L can confer a multidrug resistance phenotype. Blood 1995, 86, 1903-1910.
11. Anderson HJ, Roberge M. DNA topoisomerase II: a review of its involvement in chromosome structure, DNA replication, transcription and mitosis. Cell Biol Int Rep 1992, 16, 717-724.
12. Wang JC. DNA topoisomerases: Why so many? J Biol Chem 1991, 266, 6659-6662.
13. Wang JC, Caron PR, Kim RA. The role of DNA topoisomerases in recombination and genome stability: a double-edged sword? Cell 1990, 62, 403-406.
14. Cozzarelli NR, Wang JC, eds. DNA Topology and its Biological Effects. Cold Spring Harbor, New York, 1990.
15. Wallis JW, Chrebet G, Brodsky G, Rolfe M, Rothstein R. A hyper-recombination mutation in Saccharomyces cerevisiae identifies a novel eukaryotic topoisomerase. Cell 1989, 58, 409-419.
16. Meyn MS, Fritz E, Herzing E. Isolation and characterization of novel human cDNA with homology to yeast topoisomerase III that can suppress the radiosensitivity and hyper-recombination of ataxia telangiectasia fibroblasts. Am J Hum Genet 1995, 57, A147.
17. Aguilera A, Klein HL. HPR1, a novel yeast gene that prevents intrachromosomal excision recombination, shows carboxy-terminal homology to the Saccharomyces cerevisiae TOP1 gene. Mol Cell Biol 1990, 10, 1439-1451.
18. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989, 28, 8154-8160.
19. Tsai-Pflugfelder M, Liu LF, Liu AA, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 1988, 85, 7177-7181.
20. Jenkins JR, Ayton P, Jones T, et al. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res 1992, 20, 5587-5592.
21. Hwang J, Hwong CL. Cellular regulation of mammalian DNA topoisomerases. Adv Pharmacol 1994, 29A, 167-189.
22. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Diff 1991, 2, 209-214.
23. Zini N, Santi S, Ognibene A, et al. Discrete localization of different topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Exp Cell Res 1994, 210, 336-348.
24. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 1994, 34, 191-218.
25. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995, 270, 21429-21432.
26. Pommier Y, Tanizawa A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol 1994, 29B, 73-92.
27. Lynch TJ Jr, Kalish L, Strauss G, et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994, 12, 347-352.
28. Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granuloctye colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994, 12, 90-96.
29. Drake FH, Hofmann GA, Mong S, et al. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 1989, 49, 2578-2583.
30. Ishida R, Miki T, Narita T, et al. Inhibition of interacellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991, 51, 4909-4916.
31. Gellert M, O'Dea MH, Itoh T, Tomizawa J-I. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci USA 1976, 73, 4474-4478.
32. Sugino A, Higgins NP, Brown PO, Peebles CL, Cozzarelli NR. Engery coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci USA 1978, 75, 4838-4842.
33. Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nick-closing enzyme. Proc Natl Acad Sci USA 1977, 74, 4767-4771.
34. Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa J-I. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 1977, 74, 4772-4776.
35. Osheroff N, Zechiedrich EL, Gale KC. Catalytic function of DNA topoisomerase II. BioEssays 1991, 13, 269-275.
36. Champoux JJ. Strand breakage by the DNA untwisting enzyme results in covalent attachment of the enzyme to DNA. Proc Natl Acad Sci USA 1977, 74, 3800-3804.
37. Champoux JJ. Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme. Proc Natl Acad Sci USA 1976, 73, 3488-3491.
38. Brown PO, Cozzarelli NR. A sign inversion mechanism for enzymatic supercoiling of DNA. Science 1979, 206, 1081-1083.
39. Osheroff N, Corbett A. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by anti-neoplastic drugs. Chem Res Toxicol 1993, 6, 585-597.
40. Chen M, Beck WT. Teniposide-resistant CEM cells, which express mutant topoisomerase II α, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 1993, 53, 5946-5953.
41. Sørensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB, Westergaard O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. J Mol Biol 1992, 228, 778-786.
42. Roberge M, Tudan C, Hung SM, Harder KW, Jirik FR, Anderson H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 1994, 54, 6115-6121.
43. Frezard F, Garnier-Suillerot A. Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei. Biochim Biophys Acta 1990, 1036, 121-127.
44. Ishida R, Hamatake M, Wasserman R, Nitiss JL, Wang JC, Andoh T. DNA topoisomerase II as the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in budding yeast Saccharomyces cerevisiae. Cancer Res 1995, 55, 2299-2303.
45. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor disdioxopiperazines inhibit yeast topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994, 91, 1781-1785.
46. Kjeldsen E, Svejstrup JQ, Gromova II, Alsner J, Westergaard O. Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. J Mol Biol 1992, 228, 1025-1030.
47. Goto T, Laipis P, Wang JC. The purification and characterization of DNA topoisomerases I and II of the yeast Saccharomyces cerevisiae. J Biol Chem 1984, 259, 10422-10429.
48. Chen AY, Yu C, Bodley A, Peng LF, Liu LF. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res 1993, 53, 1332-1337.
49. Chen AY, Yu C, Gatto B, Liu LF. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci USA 1993, 90, 8131-8135.
50. Kreuzer KN, Cozzarelli NR. Escherichia coli mutants thermosensitive for DNA gyrase subunit A: effects on DNA replication, transcription and bacteriophage growth. J Bacteriol 1979, 140, 425-430.
51. Nitiss JL. Yeast as a genetic model system for studying topoisomerase inhibitors. Adv Pharmacol 1994, 29B, 201-226.
52. Zhang H, D'Arpa P, Liu LF. A model for tumor cell killing by topoisomerase poisons. Cancer Cells 1990, 2, 23-27.
53. Friedberg EC, Walker GC, Siede W. DNA Repair and Mutagenesis. ASM Press, Washington D.C., 1994.
54. Thode S, Schafer A, Pfeiffer P, Vielmetter W. A novel pathway of DNA end-to-end joining. Cell 1990, 60, 921-928.
55. Berger NA, Chatterjee S, Schmotzer JA, Helms SR. Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc Natl Acad Sci USA 1991, 88, 8740-8743.
56. Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 1992, 3, 107-111.
57. Pui C-H, Riberio RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991, 325, 1682-1687.
58. Negrini M, Felix CA, Martin C, et al. Potential topoisomerase II DNA-binding sites at the breakpoints to a t(9;11) chromosome translocation in acute myeloid leukemia. Cancer Res 1993, 53, 4489-4492.
59. Nitiss JL, Liu Y-X, Hsiung Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance to amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 1993, 53, 89-93.
60. Holm C, Goto T, Wang JC, Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell 1985, 41, 553-563.
61. Holm C, Sterns T, Botstein D. DNA topoisomerase II must act at mitosis to prevent non-disjunction and chromosome breakage. Mol Cell Biol 1989, 9, 159-168.
62. Ishida R, Miki T, Narita T, et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991, 51, 4909-4916.
63. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246, 629-633.
64. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994, 266, 1821-1828.
65. Murray AW. Creative blocks: cell-cycle checkpoints and feedback controls. Nature 1992, 359, 599-604.
66. Weinert TA, Hartwell LH. The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 1988, 241, 317-322.
67. Kohn KW, Jackman J, O'Connor PM. Cell cycle control and cancer chemotherapy. J Cell Biochem 1994, 54, 440-452.
68. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Liebermann DA. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 1995, 10, 2263-2270.
69. Agarwalo ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the Gl cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995, 92, 8493-8497.
70. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Necklers L. Taxol induction of p21 WAF1 and p53 requires c-raf-1. Cancer Res 1995, 55, 4523-4626.
71. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75, 817-825.
72. Chen X, Bargonetti J, Prives C. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 1995, 55, 4257-4263.
73. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxcity of anticancer agents. Cell 1993, 74, 957-967.
74. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin N Am 1995, 9, 451-473.
75. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994, 79, 189-192.
76. Ryan JJ, Prochownik E, Gottlieb CA, et al. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 1994, 91, 5878-5882.
77. Selvakumaran M, Lin H-K, Miyashita T, et al. Immediate early up-regulation of bax expression by p53 but not TGFb1: a paradigm for distinct apoptotic pathways. Oncogene 1994, 9, 1791-1798.
78. Downes CC, Clarke DJ, Mullinger AM, Glme'nez-Abla'n JF, Creighton AM, Johnson RT. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 1994, 372, 467-470.
79. Ishida R, Sato M, Narita T, et al. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J Cell Biol 1994, 126, 1340-1351.
80. Pommier Y, Leteurtre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994, 12, 530-542.
81. Chen AY, Liu LF. Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance. Adv Pharmacol 1994, 29B, 245-256.
82. Shou D-C, Zittoun R, Marie J-P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995, 9, 1661-1666.
83. Friche E, Nissen NI, Beck WT. MRP gene expression in heavily chemotherapy treated AML patients. Proc Am Assoc Cancer Res 1995, 36, 217.
84. Rivory LP, Chatelut E, Canal P, Mathieu-Boue A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 1994, 54, 6330-6333.
85. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991, 324, 384-394.
86. Reece RJ, Maxwell A. DNA gyrase: structure and function. Crit Rev Biochem Mol Biol 1991, 26, 335-375.
87. Nitiss JL. Using yeast to study resistance to topoisomerase II targeting drugs. Cancer Chemother Pharmacol 1994, 34, S6-S13.
88. Vassetzky YS, Alghisi G-C, Gasser S. DNA topoisomerase II mutations and resistance to anti-tumor drugs. Bioessays 1995, 767-774.
89. Andoh T, Okada K. Drug resistance mechanisms of topoisomerase I drugs. Adv Pharmacol 1994, 29B, 93-103.
90. Bugg BY, Danks MK, Beck WT, Suttle DP. Expression of mutant DNA topoisomerase II in CCRF-CEM human leukemia cells selected for resistance to teniposide. Proc Natl Acad Sci USA 1991, 88, 7634-7638.
91. Hinds M, Deisseroth K, Mayes J, et al. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistance form of topoisomerase II. Cancer Res 1991, 51, 4729-4731.
92. Lee M-S, Wang JC, Beran M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 1992, 223, 837-843.
93. Campain JA, Gottesman MM, Pastan I. A novel mutant topoisomerase II α present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry 1994, 33, 11327-11332.
94. Beck WT. DNA topoisomerases and tumor cell resistance to their inhibitors. In Shilsky R, Milano G, Ratain M, eds. Principles of Cancer Drug Pharmacology, Ch. 23. New York, Marcell Dekker, Inc., 1996, 487-501.
95. Kohno K, Danks MK, Matsuda T, Nitiss JL, Kuwano M, Beck WT. A novel mutation of DNA topoisomerase II α in an etoposide-resistant human cancer cell line. Cell Pharmacol 1995, 2, 87-90.
96. Nitiss JL, Vilalta PM, Wu H, McMahon J. Mutations in the gyrB domain of eukaryotic topoisomerase II can lend to partially-dominant resistance to etoposide and amsacrine. Mol Pharmacol 1994, 46, 773-777.
97. Hsiung Y, Jannatipour M, Rose A, McMahon J, Duncan D, Nitiss JL. Functional expression of human topoisomerase II α in yeast: mutations at amino acids 450 or 803 of topoisomerase II α result in enzymes that can confer resistance to antitopoisomerase II agents. Cancer Res 1996, 56, 91-99.
98. Fraser DJ, Brant TL, Kroll DJ. Topoisomerase II α promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells. Mol Pharmacol 1995, 47, 696-706.
99. Beck WT, Danks MK. Characteristics of multidrug resistance in human tumors. In Roninson IB, ed. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York, Plenum Press, Chapter 1, 1991, 3-55.
100. Rubin E, Kharbanda S, Gunji H, Kufe D. Activation of the c-jun protoocogene in human myeloid leukemia cells treated with etoposide. Mol Pharmacol 1991, 39, 697-701.
101. Ritke MK, Yalowich JC. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol 1993, 46, 2007-2020.
102. Kim R, Beck WT. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26. Cancer Res 1994, 54, 4958-4966.
103. Potmesil M, Hsiang YH, Liu LF, et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 1988, 48, 3537-3543.
104. Klumper E, Giaccone G, Pieters R, et al. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia. Leukemia 1995, 9, 1653-1660.
105. van der Zee AG, de Vries EG, Hollema H, Kaye SB, Brown R, Keith WN. Molecular analysis of the topoisomerase II apha gene and its expression in human ovarian cancer. Ann Oncol 1994, 5, 75-81.
106. Kaufmann SH, Karp JE, Jones RJ, et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994, 83, 517-530.
107. Giovanella BC, Stehlins JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246, 1046-1048.
108. Danks MK, Warmoth MR, Friche E, et al. Single-strand conformational polymorphism analysis of the Mr 170,00 isoyzyme of DNA topoisomerase II in human tumor cells. Cancer Res 1993, 53, 1373-1379.
109. Danks MK, Beck WT, Suttle DP. Topoisomerase II α mutation in leukemic cells from a patient with lineage switch AML. Proc Am Assoc Cancer Res 1993, 34, 333.
110. Elsea SH, Hsiung Y, Nitiss JL, Osheroff N. A yeast type II topoisomerase selected for resistance to quinolones: mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. J Biol Chem 1995, 270, 1913-1920.
111. Liu Y-X, Hsiung Y, Jannatipour M, Yeh Y, Nitiss JL. Yeast topoisomerase II mutants resistant to antitopoisomerase agents: identification and characterization of new yeast topoisomerase II mutants resistant to amsacrine and etoposide. Cancer Res 1994, 54, 2943-2951.
112. Kubo A, Nakagawa K, Fukuoka M, et al. Identification of point mutations in the alpha-topoisomerase II cDNA from human small cell lung cancer treated previously with etoposide. Proc Am Assoc Cancer Res 1995, 36, 447.
113. Zechiedrich EL, Osheroff N. Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers. EMBO J 1990, 9, 4555-4562.
114. Lindsley JE, Wang JC. Proteolysis patterns of epitopically labeled yeast DNA topoisomerase II suggest an allosteric transition in the enzyme induced by ATP. Proc Natl Acad Sci USA 1991, 88, 10485-10459.
115. Osheroff N, Corbett AH, Robinson M. Mechanism of action of topoisomerase II targeted anti-neoplastic drugs. Adv Pharmacol 1994, 29B, 105-126.